Febuxostat (Italian Wikipedia)

Analysis of information sources in references of the Wikipedia article "Febuxostat" in Italian language version.

refsWebsite

Global rank Italian rank

12nih.gov

4^th place

9^th place

9doi.org

2^nd place

7^th place

8oadoi.org

799^th place

22^nd place

1web.archive.org

1^st place

doi.org

dx.doi.org

Okamoto K, Eger BT, Nishino T, Kondo S, Pai EF, Nishino T, An extremely potent inhibitor of xanthine oxidoreductase. Crystal structure of the enzyme-inhibitor complex and mechanism of inhibition, in J. Biol. Chem., vol. 278, n. 3, gennaio 2003, pp. 1848–55, DOI:10.1074/jbc.M208307200, PMID 12421831.
Becker MA, Kisicki J, Khosravan R, et al., Febuxostat (TMX-67), a novel, non-purine, selective inhibitor of xanthine oxidase, is safe and decreases serum urate in healthy volunteers, in Nucleosides Nucleotides Nucleic Acids, vol. 23, n. 8-9, ottobre 2004, pp. 1111–6, DOI:10.1081/NCN-200027372, PMID 15571211.
Becker MA, Schumacher HR, Wortmann RL, et al., Febuxostat compared with allopurinol in patients with hyperuricemia and gout, in N. Engl. J. Med., vol. 353, n. 23, dicembre 2005, pp. 2450–61, DOI:10.1056/NEJMoa050373, PMID 16339094.
Uh M, Reid G, Febuxostat efficacy in allopurinol-resistant tophaceous gout, in J Clin Rheumatol, vol. 17, n. 4, giugno 2011, pp. 204–6, DOI:10.1097/RHU.0b013e31821c0cae, PMID 21617552.
Jackson RL, Hunt B, Macdonald PA, The efficacy and safety of febuxostat for urate lowering in gout patients ≥65 years of age, in BMC Geriatr, vol. 12, n. 1, 2012, p. 11, DOI:10.1186/1471-2318-12-11, PMC 3368715, PMID 22436129.
Schumacher HR, Becker MA, Wortmann RL, et al., Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28-week, phase III, randomized, double-blind, parallel-group trial, in Arthritis Rheum., vol. 59, n. 11, novembre 2008, pp. 1540–8, DOI:10.1002/art.24209, PMID 18975369.
Love BL, Barrons R, Veverka A, Snider KM, Urate-lowering therapy for gout: focus on febuxostat, in Pharmacotherapy, vol. 30, n. 6, giugno 2010, pp. 594–608, DOI:10.1592/phco.30.6.594, PMID 20500048.
Edwards NL, Febuxostat: a new treatment for hyperuricaemia in gout, in Rheumatology (Oxford), 48 Suppl 2, maggio 2009, pp. ii15–ii19, DOI:10.1093/rheumatology/kep088, PMID 19447778.
Hoshide S, Takahashi Y, Ishikawa T, et al., PK/PD and safety of a single dose of TMX-67 (febuxostat) in subjects with mild and moderate renal impairment, in Nucleosides Nucleotides Nucleic Acids, vol. 23, n. 8-9, ottobre 2004, pp. 1117–8, DOI:10.1081/NCN-200027377, PMID 15571212.

nih.gov

ncbi.nlm.nih.gov

Okamoto K, Eger BT, Nishino T, Kondo S, Pai EF, Nishino T, An extremely potent inhibitor of xanthine oxidoreductase. Crystal structure of the enzyme-inhibitor complex and mechanism of inhibition, in J. Biol. Chem., vol. 278, n. 3, gennaio 2003, pp. 1848–55, DOI:10.1074/jbc.M208307200, PMID 12421831.
Becker MA, Kisicki J, Khosravan R, et al., Febuxostat (TMX-67), a novel, non-purine, selective inhibitor of xanthine oxidase, is safe and decreases serum urate in healthy volunteers, in Nucleosides Nucleotides Nucleic Acids, vol. 23, n. 8-9, ottobre 2004, pp. 1111–6, DOI:10.1081/NCN-200027372, PMID 15571211.
Becker MA, Schumacher HR, Wortmann RL, et al., Febuxostat compared with allopurinol in patients with hyperuricemia and gout, in N. Engl. J. Med., vol. 353, n. 23, dicembre 2005, pp. 2450–61, DOI:10.1056/NEJMoa050373, PMID 16339094.
Khosravan R, Grabowski BA, Wu JT, Joseph-Ridge N, Vernillet L, Pharmacokinetics, pharmacodynamics and safety of febuxostat, a non-purine selective inhibitor of xanthine oxidase, in a dose escalation study in healthy subjects, in Clin Pharmacokinet, vol. 45, n. 8, 2006, pp. 821–41, PMID 16884320.
Uh M, Reid G, Febuxostat efficacy in allopurinol-resistant tophaceous gout, in J Clin Rheumatol, vol. 17, n. 4, giugno 2011, pp. 204–6, DOI:10.1097/RHU.0b013e31821c0cae, PMID 21617552.
Hilmi BA, Asmahan MI, Rosman A, Use of newly available febuxostat in a case of chronic tophaceous gout contraindicated to allopurinol and probenecid, in Med. J. Malaysia, vol. 67, n. 1, febbraio 2012, pp. 125–6, PMID 22582566.
Jackson RL, Hunt B, Macdonald PA, The efficacy and safety of febuxostat for urate lowering in gout patients ≥65 years of age, in BMC Geriatr, vol. 12, n. 1, 2012, p. 11, DOI:10.1186/1471-2318-12-11, PMC 3368715, PMID 22436129.
Hair PI, McCormack PL, Keating GM, Febuxostat, in Drugs, vol. 68, n. 13, 2008, pp. 1865–74, PMID 18729537.
Schumacher HR, Becker MA, Wortmann RL, et al., Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28-week, phase III, randomized, double-blind, parallel-group trial, in Arthritis Rheum., vol. 59, n. 11, novembre 2008, pp. 1540–8, DOI:10.1002/art.24209, PMID 18975369.
Love BL, Barrons R, Veverka A, Snider KM, Urate-lowering therapy for gout: focus on febuxostat, in Pharmacotherapy, vol. 30, n. 6, giugno 2010, pp. 594–608, DOI:10.1592/phco.30.6.594, PMID 20500048.
Edwards NL, Febuxostat: a new treatment for hyperuricaemia in gout, in Rheumatology (Oxford), 48 Suppl 2, maggio 2009, pp. ii15–ii19, DOI:10.1093/rheumatology/kep088, PMID 19447778.
Hoshide S, Takahashi Y, Ishikawa T, et al., PK/PD and safety of a single dose of TMX-67 (febuxostat) in subjects with mild and moderate renal impairment, in Nucleosides Nucleotides Nucleic Acids, vol. 23, n. 8-9, ottobre 2004, pp. 1117–8, DOI:10.1081/NCN-200027377, PMID 15571212.

oadoi.org

Okamoto K, Eger BT, Nishino T, Kondo S, Pai EF, Nishino T, An extremely potent inhibitor of xanthine oxidoreductase. Crystal structure of the enzyme-inhibitor complex and mechanism of inhibition, in J. Biol. Chem., vol. 278, n. 3, gennaio 2003, pp. 1848–55, DOI:10.1074/jbc.M208307200, PMID 12421831.
Becker MA, Kisicki J, Khosravan R, et al., Febuxostat (TMX-67), a novel, non-purine, selective inhibitor of xanthine oxidase, is safe and decreases serum urate in healthy volunteers, in Nucleosides Nucleotides Nucleic Acids, vol. 23, n. 8-9, ottobre 2004, pp. 1111–6, DOI:10.1081/NCN-200027372, PMID 15571211.
Becker MA, Schumacher HR, Wortmann RL, et al., Febuxostat compared with allopurinol in patients with hyperuricemia and gout, in N. Engl. J. Med., vol. 353, n. 23, dicembre 2005, pp. 2450–61, DOI:10.1056/NEJMoa050373, PMID 16339094.
Uh M, Reid G, Febuxostat efficacy in allopurinol-resistant tophaceous gout, in J Clin Rheumatol, vol. 17, n. 4, giugno 2011, pp. 204–6, DOI:10.1097/RHU.0b013e31821c0cae, PMID 21617552.
Schumacher HR, Becker MA, Wortmann RL, et al., Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28-week, phase III, randomized, double-blind, parallel-group trial, in Arthritis Rheum., vol. 59, n. 11, novembre 2008, pp. 1540–8, DOI:10.1002/art.24209, PMID 18975369.
Love BL, Barrons R, Veverka A, Snider KM, Urate-lowering therapy for gout: focus on febuxostat, in Pharmacotherapy, vol. 30, n. 6, giugno 2010, pp. 594–608, DOI:10.1592/phco.30.6.594, PMID 20500048.
Edwards NL, Febuxostat: a new treatment for hyperuricaemia in gout, in Rheumatology (Oxford), 48 Suppl 2, maggio 2009, pp. ii15–ii19, DOI:10.1093/rheumatology/kep088, PMID 19447778.
Hoshide S, Takahashi Y, Ishikawa T, et al., PK/PD and safety of a single dose of TMX-67 (febuxostat) in subjects with mild and moderate renal impairment, in Nucleosides Nucleotides Nucleic Acids, vol. 23, n. 8-9, ottobre 2004, pp. 1117–8, DOI:10.1081/NCN-200027377, PMID 15571212.

web.archive.org

(EN) www.nice.org.uk (PDF), su nice.org.uk, p. 22 (archiviato dall'url originale il 19 febbraio 2014).